Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Single Site Open Label Trial of the Safety and Antiviral Activity of C2F5, C2G12, and C4E10 Monoclonal Antibody Infusions in Well-Suppressed HAART-Treated Individuals Treated During Acute and Early HIV-1 Infection

NCT00219986 is registered in ClinicalTrials.gov with Rockefeller University as lead sponsor.

NCT NCT00219986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Single Site Open Label Trial of the Safety and Antiviral Activity of C2F5, C2G12, and C4E10 Monoclonal Antibody Infusions in Well-Suppressed HAART-Treated Individuals Treated During Acute and Early HIV-1 Infection
Lead sponsor
Rockefeller University
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2003
Completion date
September 30, 2005
Enrollment
12
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections